Nuclear medicine in the diagnosis of benign thyroid diseases by Czepczyński, Rafał
113
Nuclear Medicine Review 2012, 15, 2: 113–119
10.5603/NMR.2012.0008





Thyroid gland has the unique ability to concentrate iodine. This 
phenomenon offers a perfect background for a wide range of 
diagnostic tests utilizing radioactive iodine nuclides of iodine 
and technetium. Despite the very good availability of ultrasonog-
raphy and other imaging modalities, radionuclide methods 
are still inevitable in a various cases of thyroid disease. In this 
article, a comprehensive review of all these methods used in 
the diagnosis of benign thyroid diseases is presented. Iodine 
and technetium uptake tests are briefly described. Indications to 
thyroid scan in the context of iodine supply are also presented. 
Finally, the significance of thyroid findings in PET images is 
pointed out. The article is illustrated by some typical patterns 
of radionuclide thyroid images.
KEY words: iodine uptake, goitre, Graves’ disease, thyroid 
nodule
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Introduction
Thyroid gland has the unique ability to take up iodine — an es-
sential component of its hormones. The phenomenon of accumu-
lation of iodine in the thyroid gland allowed for the use of iodine 
isotopes in the diagnosis of thyroid disease as early as about 
70 years ago, although the mechanism of iodine uptake at the 
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molecular level has been carefully examined until the late twen-
tieth century. In 1939, a group of scientists from the University of 
Berkeley documented the uptake of radioactive iodine in human 
thyroid for the first time. This gave rise to first therapeutic radio-
iodine applications in patients with hyperthyroidism and thyroid 
cancer [1, 2].
Nowadays, we know that the uptake of iodine in the thyroid 
gland is attributed to the sodium-iodide symporter (NIS), described 
in 1993 by Kaminsky et al [3]. The uptake of iodine by the thyroid 
cells is still widely used in the evaluation of thyroid function by 
means of radioiodine uptake test and thyroid scintigraphy [4].
Measurement of iodine uptake 
Iodine uptake test is mainly used in patients planned for the ra-
dioiodine treatment due to hyperthyroidism. The test is performed 
using a gamma camera or a gamma probe positioned at a certain 
distance from the patient’s neck. In different centres, measure-
ments are performed at various intervals after oral administration 
of 1–3.7 MBq (30–100 mCi) 131I. Measurements made during the 
first day are essential for the assessment of iodine accumulation 
in the thyroid. Therefore, for practical reasons, measurements are 
often performed 3–6 h and 24 h after administration of the diag-
nostic dose of 131I. In centres using sophisticated techniques for 
dosimetry, measurements are performed on several consecutive 
days [5].
131I uptake in the thyroid is calculated using the formula:
IU [%] = 100 · (ct – cbkg)/c0
where:  IU — iodine uptake
 ct — number of counts registered over thyroid gland 
 cbkg — number of background counts in the room
 c0 — number of counts in the diagnostic dose registered 
 before oral administration 
Iodine uptake is a parameter with a relatively high variability. 
On average, in euthyroid patients 24 h after administration of 
diagnostic activity the uptake is ca. 25–50%. It may be higher in 
hyperthyroidism and lower in hypothyroidism (Figure 1). Apart 
from the thyroid functional status, many other, mostly iatrogenic 
factors may influence the level of thyroid iodine uptake. They are 
listed in Table 1.
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Measurement of technetium uptake 
In some centres, great attention is attached to the evalua-
tion of technetium-99m uptake in the thyroid. The concept of 
this measurement is based on the assumption that the uptake of 
99mTc by thyrocytes takes place using the same mechanism as the 
iodine and in the first 15 minutes after i.v. injection, the curves of 
99mTc and 123I run in parallel (see below). Under the conditions of 
euthyroidism, with normal iodine intake, uptake of 99mTc is 0.5–2.0%. 
As in the case of iodine uptake, this percentage decreases in hypo-
thyroidism and in iodine contamination, and increases in Graves’ 
disease and iodine deficiency. This measurement is simple and 
is performed as a supplement of thyroid scintigraphy by comparing 
the number of counts in the regions of interest located over the 
thyroid with the number of counts above the syringe containing 
the 99mTc-pertechnetate prior to injection [5–7].
Thyroid scintigraphy 
In addition to the morphological information obtained on the 
basis of ultrasonography, thyroid scintigraphy visualizes the dis-
tribution of active thyroid tissue [5]. Therefore, the general indica-
tions for scintigraphy are quite wide and include both single thyroid 
nodule, and multinodular goitre. The test is also used to evaluate 
the extent of retrosternal goitre (when ultrasound is not able to 
visualize the lower pole of the thyroid gland) and in suspected 
ectopic thyroid. In the case of goitre without clear dominance of 
one of the nodules, scintigraphy is used to select the biopsy site. 
Thyroid scintigraphy should be performed in all patients with nodu-
lar goitre undergoing treatment with radioiodine, since it allows to 
assess the anatomical distribution of active thyroid tissue, which 
may be important in the selection of therapeutic 131I activity [6–8]. 
In view of the very good availability of ultrasound and biopsy, 
a tendency to limit the indications to thyroid scintigraphy may be 
observed. In 2009–2010 American Thyroid Association (ATA) and 
the Polish Group of Endocrine Cancer published their recommen-
dations suggesting that the thyroid scintigraphy is useful only in 
patients with nodule diameter greater than 1 cm, provided that TSH 
concentration is subnormal. The role of scintigraphy in this case 
is to show whether a nodule, that is manifested in ultrasound, 
is a focus of excessive hormonal activity (hot nodule) or accu-
mulates the radiotracer at a level similar to or lower than the rest 
of the gland (warm or cold nodule). Because the hot nodules are 
rarely malignant, according to ATA guidelines fine-needle biopsy 
is not necessary in such a case. At the same time, performing 
scintigraphy in all patients with nodular goitre is not recommended 
by experts, since adequate assessment obtained with ultrasound 
and cytology is sufficient in most cases [9, 10].
Planar images are recorded in patients in a sitting or laying 
position. Anatomical reference is obtained by placing a marker over 
sternal notch. Imaging of the thyroid gland may be performed using 
several radionuclides: 99mTc, 131I and 123I. Technetium-99m (99mTc) 
is administered intravenously in the form of pertechnetate, obtained 
from a molybdenum-technetium generator. The permanent avail-
ability of 99mTc in nuclear medicine departments, made it the most 
widely used nuclide in the routine endocrine diagnosis (Figure 2).
99mTc-pertechnetate as an analogue of iodine is transported to 
thyroid cells in a similar way as the isotopes of iodine, i.e. by the 
means of NIS. The maximal accumulation of 99mTc-pertechnetate 
is obtained 15–20 minutes after i.v. administration. In this initial 
phase, the increase of 99mTc activity in thyroid runs parallel to the 
increase of activity of intravenous 123I. The percentage of 99mTc 
accumulated in thyrocytes reflects the dynamics of absorption of 
iodine to the thyroid tissue. After 15–30 min, however, the curve 
of the thyroid 99mTc activity reaches a plateau and then decreases, 
while the uptake of iodine is still increasing. This results from the 




























— potassium iodide (e.g. Jodid)
— Lugol’s solution
— some eye-drops
— vitamin preparations (e.g. Feminatal)
Thyroid hormone preparations:
— L-thyroxin (Euthyrox, Letrox)
— L-triiodothyronin (Thybon, Cytomel, Novothyral)
Anti-thyroid drugs (methimazole, propylthiouracil)
Iodine-containing i.v. contrast agents
























— recombinant thyrotropin (rhTSH, Genotropin)
Figure 1. Kinetics of iodine uptake by the thyroid gland in different 
conditions. In patients with Graves’ disease with significant hyperthy-
roidism (green line) the result of an early measurement (after 6 h) may 
be higher or close to the late measurement (after 24 h), due to the ac-
celeration of iodine turnover in the gland
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fact that the 99mTc-pertechnetate is not subject to the organifica-
tion (as in case of iodine), and is washed-out from the thyrocytes.
In the interpretation of scintigraphic images obtained with 
99mTc, it should be noted that the uptake of 99mTc is not limited 
strictly to the thyroid tissue. There is some physiological uptake of 
99mTc-pertechnetate in the salivary glands, gastric mucosa, as well 
as a relatively high background activity from the vessels.
High availability is not the only advantage of 99mTc. From the 
physical point of view 99mTc is preferred due to low energy of the 
gamma photons (140 keV) and relatively short half-life (6 h). Thus, 
it is possible to use much higher activity than 131I and to register 
more accurate images in a shorter acquisition time. Moreover, 
despite 20-fold higher activity of 99mTc, the absorbed dose is about 
300 times lower than with the diagnostic dose of 131I [5, 7].
The iodine isotopes: 123I and 131I are also used for thyroid 
scintigraphy. In terms of physical properties, 123I is similar to 
99mTc – is a pure gamma-emitter, and its gamma photons are also 
characterized by relatively low energy (159 keV) and short half-life 
(13 h). The advantage of 123I is the higher specificity and persis-
tence of accumulation in the thyroid caused by the organification. 
Due to these properties, later acquisitions can be performed and 
accurate kinetics of iodine in the thyroid tissue may be evaluated. 
Long-term and higher accumulation of radionuclide in the thyroid 
in comparison to 99mTc, result in even more detailed images, with 
a clearer demarcation of thyroid tissue from the surrounding 
structures. It is believed that 123I is an ideal radionuclide for the 
assessment of thyroid - both in benign diseases and in cancer. 
Unfortunately, due to its low availability (it is produced in cyclotron) 
and high cost, it is not used routinely in all institutions. In Polish 
conditions, 123I is used occasionally [7, 9, 11].
131I, often called radioiodine, is the most commonly used 
radioactive isotope of iodine. This nuclide emits both, beta and 
gamma radiation with a half-life of 8.1 d. The energy of gamma 
rays used for diagnostic purposes, is 364 keV. Because of these 
disadvantages in comparison to 99mTc and 123I, the use of 131I 
scintigraphy should be limited to the monitoring of treatment in 
patients with differentiated thyroid cancer. In case of benign thy-
roid disease, scintigraphy with 131I is justified if 123I is unavailable, 
in following indications:
 — evaluation of retrosternal and mediastinal goitre;
 — differentiation of mediastinal tumour and goitre;
 — detection of ectopic thyroid tissue (sublingual or ovarian 
goitre);
 — congenital hypothyroidism in differential diagnosis of thyroid 
agenesis and ectopy [5, 7].
The characteristics of various nuclides used for the visualiza-
tion of the thyroid gland are shown in Table 2 [6, 8, 9, 12]. 
Images of the thyroid obtained using 99mTc, and one of the 
isotopes of iodine do not differ significantly. Only a few cases of 
differentiated thyroid cancer with accumulation of 99mTc and no 
uptake of 131I were reported. This phenomenon occurred when 
registration of 99mTc images was started too early, when the accu-
mulation of radiotracer in the tumour corresponded to significantly 
increased perfusion [11].
While interpreting results of thyroid scintigraphy, the physician 
should be aware of the current situation of the patient: 
 — history of thyroid disease;
 — ultrasound image or report (optimally, the doctor performs ultra-
sound on his own);
 — current TSH;
 — used drugs, in particular thyroid hormones, antithyroid 
drugs and iodine-containing agents (amiodarone, disinfectant 
and expectorant drugs) (Figure 3).
Table 2. Comparison of nuclides used for thyroid scintigraphy
99mTc 123I 131I
Uptake mechanism NIS, then washout NIS + organification NIS + organification
Background activity Rather high Low Low
Photon energy Gamma 140 keV Gamma 159 keV Gamma 364 keV + beta












Ddministration i.v. p.o. or i.v. p.o. or i.v.
Start of acquisition 15–30 min 6–8 h 24 h
Recommended collimators Low-energy, pinhole Low-energy, pinhole High-energy, pinhole
Average effective dose equivalent 0,013 mSv 1,9 mSv 6,6 mSv
*SNM recommends a higher activity of 99mTc –75–370 MBq (2–10 mCi)
Figure 2. Thyroid scan — normal image
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The report of the thyroid scan should contain: 
 — the location of thyroid tissue (normal, ectopic, retrosternal goitre);
 — structure and size of the gland (symmetry of the lobes, py-
ramidal lobe); it should be noted that scintigraphy is not able 
to accurately determine the diameters of the thyroid lobes, 
especially in the sagittal axis (thickness); therefore, the de-
scription of size should be limited to reporting clear deviation 
from normal size;
 — the tracer distribution in the thyroid, foci of increased or 
decreased tracer accumulation (warm, hot or cold nodules).
Assessment of uptake in a thyroid focus is important in 
terms of malignancy risk-stratification. The highest probability of 
malignancy is found in nodules with reduced tracer uptake, so 
called cold nodules (Figure 4). The probability is mainly depend-
ant on iodine supply in the population: in countries with relatively 
low iodine intake the risk ranges from 5 to 10% (Austria 5.5%, Italy 
8.2%), while in countries with a high supply — more than 10% (UK 
11.4%, U.S. 20.5%) [13–15]. Of course, this statistics does not 
indicate that the iodine supply increases the risk of thyroid cancer 
— on the contrary, in populations with high iodine supply focal 
lesions occur less frequently, hence the relative occurrence of 
thyroid cancer among all cases of nodular disease is higher than 
in populations with a high incidence of nodular goitre (Figure 5).
In Poland, it may be presumed that about 10% of cold solid nod-
ules are malignant. Among other solid lesions manifested as a cold 
focus, benign nodules such as non-secreting thyroid adenomas are 
most frequent. It should be noted that the areas of fluid, i.e. colloid 
and posthemorrhagic cysts by definition do not show tracer uptake. 
Therefore presence of a cold area consistent with an anechoic fo-
cus in the ultrasound practically excludes the diagnosis of malignancy. 
The presence of tracer uptake in a focal lesion (Figure 6, 7) 
does not exclude thyroid cancer, but the negative predictive value 
of a hot nodule image is very high [11]. It should be stressed that 
spatial resolution of scintigraphy is relatively low (ca. 1–2 cm). 
Therefore, smaller changes showing no tracer uptake may not be 
visualized, especially when they are surrounded by a thick layer of 
normal tissue. Such changes may be falsely classified as warm 
nodules. In some cases, it may be possible to image smaller 
lesions, but only if they are located at the anterior surface of the 
gland, and the lobe is not very thick (Figure 8, 9) [7].
There have been reports about the utility of thyroid imaging 
using methoxyisobutylisonitrile (99mTc-MIBI). Uptake of this tracer 
in the mitochondria of cancer cells is associated with an increased 
number and activity of mitochondria, as well as with increased 
perfusion of the lesion. It has been suggested that the 99mTc-MIBI 
scan should be used in case of inconclusive biopsy and/or cold 
nodule (Figure 10). Clinical trials have not yielded conclusive 
results and therefore this method was not included in the guide-
lines of the management of thyroid nodular disease [16, 17]. There 
are, however data that indicate that a negative scintigraphy using 
99mTc-MIBI practically excludes malignancy [18]. Recently, possible 
benefits of SPECT/CT technology in image registration performed 
using 99mTc-MIBI have been discussed [19].
Increased but homogenous tracer uptake in the thyroid is char-
acteristic of Graves’ disease. Thyroid gland is often enlarged, but 
may also have a normal size.
The diagnosis of Graves’ disease does not exclude the 
presence of thyroid nodules. Hyperthyroidism of autoimmune 
origin with the presence of focal lesions in the thyroid is known 
Figure 3. Thyroid scintigraphy in case of low iodine uptake, the patient 
with hyperthyroidism previously treated with amiodarone
Figure 4. Cold nodule in the upper part of the right thyroid lobe
Figure 5. Toxic nodular goitre — a patient admitted for a radioiodine 
therapy of hyperthyroidism. In the right lobe, an area of increased 
tracer accumulation, i.e. warm nodule is found. In the left lobe an area 
with no tracer uptake is visible. In hyperthyroidism, this area does not 
have to represent a cyst or malignancy and may correspond to normal 
thyroid tissue, with deficient hormonal activity caused by TSH sup-
pression
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as Marine-Lenhart syndrome (Figure 11). Thyroid scintigraphy in 
this syndrome is of particular value since the risk of thyroid cancer 
in a cold nodule in Graves’ disease is higher than in a cold nodule 
without autoimmune thyroid disease and is estimated for 15–19% 
[20, 21]. In addition, thyroid cancer coexisting with Graves’ disease 
is clinically more aggressive, that is attributed to the stimulating 
effect of the thyroid antibodies [22].
The initial phase of de Quervaine thyroiditis may be accom-
panied by painful swelling of the thyroid and elevated levels of 
fT3 and fT4. The thyroid image is characterized by reduced and 
Figure 6. Warm nodule of the left lobe
Figure 7. Hot nodule of the left lobe. Autonomous adenoma causes 
complete suppression of TSH. At the same time, normal thyroid tissue 
is inactive and does not accumulate the tracer
Figure 8. Multinodular goitre with several warm nodules
Figure 9. Large multinodular goitre with warm and cold areas. The 
lower portion of the gland penetrates into the superior mediastinum
Figure 10. Scintigraphy with 99mTc-MIBI. A nodule at inferior pole of the right thyroid lobe shows normal uptake of 99mTc (right image), and increased 
uptake of 99mTc-MIBI (middle image). Subtraction image (left) shows activity only in the nodule. Uptake of 99mTc-MIBI in a thyroid lesion indicates 
relatively high probability of malignancy
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very inhomogenous tracer distribution, especially in the area of 
inflammatory process.
Suppression thyroid scintigraphy
The aim of a suppression scan is to visualize autonomous thy-
roid tissue, i.e. functioning independently of the hypothalamic-pi-
tuitary-thyroid axis. It involves the performance of thyroid scinti-
graphy with a radioiodine uptake measurement before and after 
administration of triiodothyronine or thyroxine preparation for 7–14 
days. The recommended daily dose is 80 mcg L-triiodothyronine 
or 150 mcg of levothyroxine. In a normal gland, thyroid hormone 
decreases the radioactive iodine accumulation by at least 50%. No 
change or reduction of iodine uptake less than 30% indicates the 
autoimmune process. This test can also be done by measuring 
99mTc uptake instead of iodine. An autonomous nodule that is warm 
at baseline image converts to a hot nodule as the surrounding 
normal tissue becomes suppressed. Therefore in some centres, 
suppression test is also used for preparation to radioiodine treat-
ment of a non-toxic nodular goitre [5, 7].
Potassium perchlorate test
Potassium perchlorate test is used to evaluate disorders of iodine 
organification. In normal conditions after the influx into the cell via 
NIS, the iodide ions are rapidly oxidized by thyroid peroxidase, and 
are subsequently incorporated into tyrosyl residues of thyroglobulin. 
This process takes no more than 2–3 h [7]. In the case of an organifi-
cation defect (peroxidase defect in Pendred syndrome), free iodine, 
which has not been organified, is washed out of the cell. Potassium 
perchlorate inhibits the NIS activity, reducing the flow of iodide into the 
cell. Thus, in case of deficient peroxidase the content of iodine in the 
thyroid gland is reduced after administration of perchlorate because 
of iodine wash-out. The test consists of iodine uptake measurement 
2-3 h after intravenous injection of 123I or oral administration of 131I, 
followed by a next measurement 2 h after oral administration of 
potassium or sodium perchlorate (0.6–1.0 g of Irenat). Decrease in 
iodine uptake by 20% confirms the organification defect. In healthy 
subjects, iodine uptake after administration of perchlorate should 
not be reduced [5].
Positron emission tomography (PET)
PET using 18F-FDG is widely used in the diagnosis of differenti-
ated thyroid carcinoma. As this paper is limited to the diagnosis of 
benign thyroid disease, the use of PET in thyroid cancer will not 
be discussed here. The diagnosis of benign thyroid disease us-
ing PET is not recommended, but there are clinical situations in 
which a thyroid problem is detected incidentally in a PET/CT scan.
In oncology, PET/CT using 18F-FDG is used to differentiate 
between benign and malignant lesions, e.g. in case of a single 
pulmonary nodule. In thyroid practice, a common problem is to 
determine the indications for surgery in case of an inconclusive 
biopsy or in case of a follicular neoplasm. In these situations, the 
role of PET is not clear. In several prospective studies image of 
a metabolically active thyroid nodule was characterized by rela-
tively low positive predictive value (PPV from 33 to 50%). 18F-FDG 
uptake may occur also in a number of benign lesions. Moreover, 
the level of glucose metabolism expressed by the standardized 
uptake value (SUV) in the focal lesion did not improve the diagnos-
tic performance of PET [23–25]. What is of particular interest, the 
negative predictive value is close to 100% caused by a very low 
number of false-negative results, i.e. thyroid malignancy almost 
always shows some metabolic activity. Therefore, the role of PET 
might rely on reducing the number of thyroidectomy in patients with 
equivocal biopsy results, although certainly the use of this study 
to evaluate thyroid nodules is not economically justified [25, 26].
Another problem is the occurrence of abnormal thyroid 
18F-FDG activity in patients undergoing PET/CT for other reasons. 
Normal thyroid does not utilize glucose. 18F-FDG uptake in the thy-
roid gland is observed in approximately 2% of PET studies [23, 24]. 
It can be either focal or diffuse. Retrospective studies performed 
on thousands of PET and PET/CT images, showed that the prob-
ability of thyroid cancer in case of incidentally detected focal 
metabolic activity in the thyroid (so-called incidentalomas, Figure 
12) varies from 27 to 47% [27–29].
On the other hand, diffuse, moderate accumulation of 18F-FDG 
in the entire gland indicates inflammatory process, usually associ-
ated with chronic Hashimoto thyroiditis (Figure 13). 
Figure 11. Marine-Lenhart syndrome. A cold nodule in a diffuse goitre 
caused by Graves’ disease Figure 12. Focal activity of 18F-FDG in the left lobe of the thyroid in 
PET / CT performed in a patient with lymphoma. The patient was treat-
ed surgically — papillary thyroid cancer was diagnosed
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In conclusion, incidental detection of metabolically active 
thyroid nodule should be followed by biopsy to exclude thyroid car-
cinoma, while in case of diffuse 18F-FDG uptake, TSH and thyroid 
antibodies (aTPO, aTg) measurements should be recommended.
In some centres positron-emitting iodine isotope 124I is avail-
able. Its half-life is 4.2 d. The PET/CT with 124I allows for more 
precise images than routine 131I scintigraphy, with the advantage 
of no effect on the thyroid stunning [30]. This method is useful only 
in the diagnosis of differentiated thyroid carcinoma.
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